The 5 Pillars of Life Sciences IPO Readiness

Tom Shoemaker, Kenneth Cordell, Drew Thieme

Business professionals collaborating as they discuss strategies for life sciences IPO readiness and public market success.

Life sciences organizations preparing for an IPO face atypical expectations. Our team covers how to strengthen IPO readiness in five key areas.

For many companies, an initial public offering (IPO) is viewed as a financing event, but going public represents a much broader structural transformation for life sciences organizations. Public companies operate under a level of scrutiny and accountability that makes leadership teams responsible not only to existing investors but also to analysts, regulators, institutional shareholders, and the broader market.

For biotech, medtech, and other life sciences companies, the transition can be especially complex because valuation frequently is driven by clinical progress, regulatory milestones, and execution capability in addition to traditional financial performance. As a result, IPO readiness for life sciences organizations extends well beyond Securities and Exchange commission (SEC) filings or capital raising. It requires organizations to demonstrate maturity across five interconnected areas.

1. Strategy: Align the IPO with long-term objectives

An IPO should support a life sciences organization’s broader growth strategy, which, for many life sciences companies, often exceeds simple capital needs. While an IPO can provide liquidity for founders and early investors, it also can give clinical-stage companies access to broader capital markets to help fund costly, long-term clinical development programs.

As Phase 2 and Phase 3 trials increase capital demands, public markets can offer financing scale that private markets and traditional debt structures often cannot support. But going public also can help support employee compensation plans, attract senior talent, and even enable strategic transactions.

Timing is another vital part of strategy, as market conditions, investor appetite, and clinical milestones all can influence IPO success. Many organizations begin readiness planning 18 to 24 months before a potential transaction to allow time to strengthen infrastructure and prepare for public-company expectations.

“Public markets can offer scale that private markets sometimes cannot, especially when the company needs hundreds of millions of dollars rather than tens of millions.”^*

2. Science: Build a credible investment story

Science might be what drives the valuation for life sciences companies, but if organizations can’t craft a compelling, credible story around that science, their valuation can suffer. Investors want to put their money into differentiated science with scalable commercial potential. A complete story around the science should include four main components:

An understanding of the unmet medical need, including a clearly defined patient population, a meaningful market, and proof that the therapy addresses a real gap
Clinical differentiation, including a rationale for why the therapy is better than alternatives
Intellectual property position, including strong patents with sufficient life so investors can anticipate durability of value
Long-term commercial opportunity associated with a company’s programs, with clearly defined pipeline expansion potential

The market often has a more favorable view of organizations with compelling data, clear regulatory pathways, and opportunities for expansion.

“Strong science builds the foundation, but it must be paired with credible execution. All of these factors will affect which investors are interested in the company and how much they are willing to invest in the IPO.”^*

3. Operations: Demonstrate execution capability

Operational readiness reflects whether a company can execute its clinical and commercial strategies.

Investors frequently evaluate:

Clinical trial planning, assessing whether enrollment assumptions appear realistic, end points align with regulatory expectations, and development timelines are achievable
Regulatory planning, assessing if organizations have a clear understanding of approval pathways, milestone sequencing, and potential opportunities for accelerated designations where applicable
Manufacturing and supply chain considerations, with companies approaching commercialization or later-stage development often facing greater scrutiny around scalability, vendor management, and operational continuity
Operational planning, as investors want to understand whether major milestones can be achieved within the company’s anticipated funding runway and whether management has identified potential delays or execution risks

Strong operational discipline is vital to help reinforce confidence in management’s ability to deliver results.

“Investors want to see an organization that is operationally disciplined and not just scientifically ambitious. Execution discipline naturally connects to financial discipline.”^*

4. Finance: Establish financial readiness

Public investors expect transparency around capital planning and financial reporting, so there must be an alignment between the company’s operating plan and its capital plan. Life sciences organizations should be able to articulate how proceeds will support key milestones and how management is evaluating future funding needs and operational scenarios. Companies also should assess whether their finance function is prepared for SEC reporting requirements, GAAP-compliant reporting, and Public Company Accounting Oversight Board audit standards.

If a company’s finance team is small or stretched too thin, management might need to engage additional consultants to assist with IPO preparation, the registration statement, and future SEC filing requirements.

“Finance is where credibility becomes quantifiable, because investors want to know exactly how capital will advance the program. Financial discipline underpins investor confidence.”^*

5. Governance: Prepare for public-company expectations

Governance readiness can shape how investors assess organizational maturity, particularly for companies entering the public markets for the first time. Management experience and board composition often are important factors for investors. Other considerations include:

Internal controls
Compliance infrastructure
Reporting processes
Current governance processes

Outside advisers also play a key role. Experienced auditors, securities counsel, and IPO advisers can help companies navigate technical reporting requirements, governance expectations, and regulatory considerations throughout the transaction process.

“Many investors will agree to invest in the IPO only if there is an experienced management team that has had previous relevant success. Some investors even consider the track record of the management team as the most important factor in the company, even more than the science.”^*

For life sciences companies, IPO readiness is not isolated to a single department or workstream. Strategy, science, operations, finance, and governance all influence how investors evaluate the organization, and companies that begin planning early are often better positioned to identify readiness gaps, strengthen infrastructure, and prepare for the demands of operating as a public company. Ultimately, IPO readiness for life sciences companies requires building the foundation needed to support long-term credibility and performance in the public markets.

^* “Preparing for a Life Sciences IPO in Today’s Market,” webinar, Crowe, March 12, 2026.

Life sciences audit services

We understand the life cycle of life sciences companies and how to meet your needs.

Explore our services

Contact our team

Our team has extensive experience in helping life sciences companies go public. Plus, working with our team means you can have access to specialists in many different areas. Contact us today to see how we can help your organization.